Skip to main content
OpenTrials

Clinical trial condition

Leukemia, Myeloid, Acute

Explore clinical trials studying Leukemia, Myeloid, Acute. Study availability and eligibility vary by location and protocol.

2,459 public trials 541 recruiting studies
Refine in advanced search Browse all conditions

Leukemia, Myeloid, Acute trial results

Active, Not Recruiting

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685

Conditions
Acute Leukemia, Acute Lymphoid Leukemia, Acute Myeloid Leukemia, +31 more
Locations
  • City of Hope Duarte, California, United States
  • Ronald Reagan UCLA Medical Center Los Angeles, California, United States
  • UC Davis Sacramento, California, United States
  • Stanford Health Care Stanford, California, United States
View all 21 locations
View Trial Details
Active, Not Recruiting

Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

NCT03953898

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, +13 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • Yale University New Haven, Connecticut, United States
  • UM Sylvester Comprehensive Cancer Center at Coral Gables Coral Gables, Florida, United States
  • UM Sylvester Comprehensive Cancer Center at Deerfield Beach Deerfield Beach, Florida, United States
View Trial Details
Active, Not Recruiting

BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid Leukemia

NCT04284787

Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy, +8 more
Locations
  • Smilow Cancer Hospital Care Center at Greenwich Greenwich, Connecticut, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
  • Yale University New Haven, Connecticut, United States
  • MedStar Georgetown University Hospital Washington D.C., District of Columbia, United States
View all 29 locations
View Trial Details
Active, Not Recruiting

Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML

NCT02091245

Conditions
Bone Marrow Diseases, Chronic Disease, Chronic Myelogenous Leukemia (CML) in Blast Crisis, +26 more
Locations
  • UCSF San Francisco, California, United States
  • Children's Hospital Colorado Aurora, Colorado, United States
  • Children's Healthcare of Atlanta Atlanta, Georgia, United States
  • Boston Children's Hospital Boston, Massachusetts, United States
View Trial Details
Active, Not Recruiting

Testing Nivolumab to Prevent Disease From Coming Back After Treatment in Patients With Acute Myeloid Leukemia, REMAIN Trial

NCT02275533

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Banner University Medical Center - Tucson Tucson, Arizona, United States
  • University of Arizona Cancer Center-North Campus Tucson, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
View all 46 locations
View Trial Details
Active, Not Recruiting

FLT PET/CT in Measuring Response in Patients With Previously Untreated Acute Myeloid Leukemia

NCT02392429

Conditions
Acute Myeloid Leukemia, Hematologic Diseases, Hemic and Lymphatic Diseases, +5 more
Locations
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
  • Washington University School of Medicine St Louis, Missouri, United States
  • Mount Sinai Hospital New York, United States
  • UNC Lineberger Comprehensive Cancer Center Chapel Hill, North Carolina, United States
View Trial Details
Active, Not Recruiting

Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

NCT02632708

Conditions
AML Arising After Exposure to Genotoxic Injury, AML Arising From Antecedent Hematologic Disorder (AHD), AML Arising From Myelodysplastic Syndrome (MDS), +9 more
Locations
  • City of Hope Duarte, California, United States
  • UCLA Medical Center Los Angeles, California, United States
  • University of Colorado Aurora, Colorado, United States
  • University of Chicago Chicago, Illinois, United States
View all 17 locations
View Trial Details

Related conditions